CABERGOLINE (cabergoline) by Teva is d2 receptors. Approved for hyperprolactinemic disorders, either idiopathic, due to pituitary adenomas in adults. First approved in 2018.
Drug data last refreshed 1w ago
D2 receptors. Results of in vitro studies demonstrate that cabergoline exerts a direct inhibitory effect on the secretion of prolactin by rat pituitary lactotrophs. Cabergoline decreased serum prolactin levels in reserpinized rats. Receptor-binding studies indicate that cabergoline has low affinity…
Ergot Derivative
Worked on CABERGOLINE at Teva? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Cabergoline for the Treatment of Chronic Pain Due to Endometriosis
Cabergoline Combined Hydroxychloroquine/Chloroquine to Treat Resistant Prolactinomas
Study of the Efficacy and Safety of Pasireotide s.c. +/- Cabergoline in Patients With Cushing's Disease
Study On Utilization Of Cabergoline For Compliance With Risk Minimization Activities (SUCRE)
Efficacy of Octreotide Acetate and Cabergoline in Patients With Acromegaly